Science - USA (2021-11-05)

pathways that may enable therapeutic ap-
proaches to alter the fitness of mutant clones.

REFERENCES AND NOTES

1. J. N. Cooper, N. S. Young,Blood 130 , 2363– 2372
   (2017).


2. G. Genoveseet al.,N. Engl. J. Med. 371 , 2477–2487 (2014).


3. S. Jaiswalet al.,N.Engl.J.Med. 371 , 2488– 2498
   (2014).


4. Z. Tothovaet al.,Cell Stem Cell 21 , 547–555.e8 (2017).


5. X. Shiet al.,Exp. Hematol. 64 , 33–44.e5 (2018).


6. J. Henningeret al.,Nat. Cell Biol. 19 , 17–27 (2017).


7. R. Soodet al.,Blood 115 , 2806–2809 (2010).


8. H. A. David,Biometrika 55 , 573–575 (1968).


9. D. Traveret al.,Nat. Immunol. 4 , 1238–1246 (2003).


10. J. Ablain, E. M. Durand, S. Yang, Y. Zhou, L. I. Zon,Dev. Cell 32 ,
    756 – 764 (2015).


11. A. Alemany, M. Florescu, C. S. Baron, J. Peterson-Maduro,
    A. van Oudenaarden,Nature 556 , 108–112 (2018).


12. F. E. Mooreet al.,J. Exp. Med. 213 , 979–992 (2016).
    13. S. Jaiswalet al.,N. Engl. J. Med. 377 , 111–121 (2017).
    14. A. G. Bicket al.,Nature 586 , 763–768 (2020).
    15. K. A. Matatallet al.,Cell Rep. 17 , 2584–2595 (2016).
    16. D. Hormaechea-Agullaet al.,Cell Stem Cell 28 , 1428–1442.e6
    (2021).
    17. D. C. Bellissimoet al.,Blood Adv. 4 , 1145–1158 (2020).
    18. S. Safeet al.,J. Steroid Biochem. Mol. Biol. 157 , 48– 60
    (2016).

ACKNOWLEDGMENTS

We thank P. Liu for therunx1mutant zebrafish, J. Mito for

assistance with planning the scRNA-seq experiment with

TWISTR zebrafish, B. Gheller for assistance with GSEA, and

colleagues for critical reading of the manuscript.Funding:NIH

grants P01HL131477 (L.I.Z.) and 5F31HL126338-03 (J.E.H.),

Pedal for Pediatrics (S.A.), and Alex’s Lemonade Stand

Foundation and Babich Family Foundation Familial RUNX1

grant (L.I.Z.) L.I.Z. is a Howard Hughes Medical Institute

Investigator.Author contributions:Conceptualization: S.A.,

J.E.H., W.P.M., L.I.Z.; methodology: S.A., J.E.H., W.P.M.;

investigation: S.A., J.E.H., W.P.M., M.C.W., J.L.M.; visualization:

S.A., J.E.H.; funding acquisition: S.A., J.E.H., L.I.Z.; project

administration: S.A., J.E.H.; resources: S.Y.; software: M.M., J.Y.;

supervision: S.A., J.E.H., L.I.Z.; writing–original draft: S.A.,

J.E.H.; writing–review and editing: S.A., J.E.H., L.I.Z. All authors

commented on the manuscript.Competing interests:L.I.Z.

is a founder and stockholder of Fate Therapeutics,

CAMP4Therapeutics, and Scholar Rock. All other authors

declare that they have no competing interests.Data and

materials availability:All data are available in the main text or

the supplementary materials. The scRNA-seq data have been

deposited in GEO under accession code GSE176037.

SUPPLEMENTARY MATERIALS

science.org/doi/10.1126/science.aba9304

Materials and Methods

Figs. S1 to S10

Tables S1 and S2

References ( 19 – 33 )

16 January 2020; accepted 20 September 2021

10.1126/science.aba9304

772 5 NOVEMBER 2021¥VOL 374 ISSUE 6568 science.orgSCIENCE

RESEARCH | REPORTS